Protein and Energy Metabolism in Pediatric Crohn's Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Indiana University.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
GlaxoSmithKline
Crohn's and Colitis Foundation
Information provided by:
Indiana University
ClinicalTrials.gov Identifier:
NCT00583232
First received: December 20, 2007
Last updated: June 22, 2011
Last verified: June 2011
  Purpose

The metabolic response to Crohn's disease, including increased proteolysis and lipolysis and changes in energy expenditure, plays a significant role in the resulting malnutrition from which these patients suffer. Tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine, has been found to be elevated in children with ulcerative colitis. TNF-alpha has been incriminated in the mechanism of weight loss in many different chronic diseases, and causes net protein and lipid catabolism. Anti-TNF-alpha antibody (infliximab) has been proven to be an effective therapy for ulcerative colitis.

The purpose of this study is to compare changes in protein and lipid metabolism, as well as resting energy expenditure, before and after therapy with anti-TNF-alpha antibody (infliximab) or corticosteroids in children with recurrent Crohn's disease. Performing this study will better define the changes in nutrition status observed in these children following remission of active Crohn's disease, and potentially lead to changes in medical and nutritional management of these children.


Condition Intervention
Crohn's Disease
Protein Metabolism
Energy Metabolism
Other: Stable isotope infusions

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Protein and Energy Metabolism in Pediatric Crohn's Disease

Resource links provided by NLM:


Further study details as provided by Indiana University:

Primary Outcome Measures:
  • Compare whole body and splanchnic protein kinetics and balance in response to corticosteroid and anti-TNF-alpha therapies in the fasting state and during enteral nutrition infusion. [ Time Frame: Week 0, 2 and 14 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compare the effects of corticosteroid and anti-TNF-alpha therapies on resting and total energy expenditure. [ Time Frame: Week 0, 2 and 14 ] [ Designated as safety issue: No ]
  • Compare the effects of corticosteroid and anti-TNF-alpha therapies on free fatty acid metabolism [ Time Frame: Week 0, 2 and 14 ] [ Designated as safety issue: No ]
  • Compare the effects of corticosteroid and anti-TNF-alpha therapies on quality of life [ Time Frame: Week 0, 2, and 14 ] [ Designated as safety issue: No ]
  • Comparing the effects of corticosteroid and anti-TNF-alpha therapies on bone turnover and bone density [ Time Frame: Week 0,2 and 14 ] [ Designated as safety issue: No ]
  • Compare the effects of corticosteroid and anti-TNF-alpha therapies on body composition. [ Time Frame: Week 0, 2 and 14 ] [ Designated as safety issue: No ]
  • Compare the effects of corticosteroid and anti-TNF-alpha therapies on cytokines known to be altered in inflammatory bowel disease. [ Time Frame: Week 0, 2 and 14 ] [ Designated as safety issue: No ]
  • Compare the effects of corticosteroid and anti-TNF-alpha therapies on vascular endothelial function. [ Time Frame: Week 0, 2 and 14 ] [ Designated as safety issue: No ]

Estimated Enrollment: 34
Study Start Date: February 2006
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Corticosteroid
Subjects receiving corticosteroid therapy (1-2 mg/kg/day up to 60mg/day) with taper.
Other: Stable isotope infusions
Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
Active Comparator: infliximab
Subjects receiving infliximab therapy (5 mg/kg at 0, 2 and 6 weeks, followed by every 8 week therapy)
Other: Stable isotope infusions
Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.

  Eligibility

Ages Eligible for Study:   6 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female children between the ages of six and eighteen years of age with recurrence of active Crohn's disease, determined by their primary pediatric gastroenterologist to require either:

    1. Corticosteroid therapy ((1-2 mg/kg/d up to maximum of 60 mg/day) with taper, or
    2. Infliximab therapy (5 mg/kg at 0, 2, and 6 weeks, followed by q 8 week therapy)
  • Crohn's disease of at least 3 months since diagnosis, with gastritis, duodenitis, ileitis, ileocolitis, or colitis, confirmed by endoscopy and biopsy
  • PCDAI score >20
  • If receiving concomitant medications, must have been on a stable regimen as follows:

    1. Subjects on aminosalicylates and/or immunomodulators should be on a stable dose for at least 2 weeks prior to enrollment.
    2. Subjects must be off oral, rectal, and parenteral corticosteroids at least 2 weeks prior to enrollment.
  • Screening laboratory tests that meet the following criteria (obtained within 4 weeks of enrollment):

    1. Hemoglobin >8.0 g/dL
    2. White blood cell count >3.5 x 109/L
    3. Neutrophils >1.5 x 109/L
    4. Platelets >100 x 109/L
    5. Aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels within 3 times the upper limit of normal.
  • For those patients to receive infliximab, PPD skin tests with skin induration <5 mm.
  • Signed written consent from the parent/legal guardian and assent from the child to be obtained prior to enrollment.

Exclusion Criteria:

  • Local manifestations of Crohn's disease, including fistula(s), strictures, abscesses, or other complications for which surgery may be indicated.
  • Surgery for bowel diversion with placement of stoma within 3 months prior to screening.
  • Positive stool examination of enteric pathogens including Salmonella and Shigella species, Clostridium difficile, and Giardia lamblia.
  • Female subjects who are pregnant, nursing, or planning pregnancy.
  • Concomitant diagnosis or history of congestive heart failure.
  • Treatment with parenteral nutrition within 4 weeks of enrollment.
  • Serious infection in the 3 months prior to enrollment.
  • History of prior or current active or latent tuberculosis.
  • Immune deficiency syndrome, including documented human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
  • History of systemic lupus erythematosus.
  • A transplanted organ.
  • Known malignancy or history of malignancy within 5 years of enrollment.
  • History of demyelinating disease.
  • History of substance abuse.
  • Poor tolerability of venipuncture or lack of venous access during the study period.
  • A live virus vaccination within 3 months of enrollment.
  • Prior history of infliximab infusion, or any other therapeutic agent targeted at reducing tumor necrosis factor-a (TNF-a).
  • Hypersensitivity to any murine proteins or other component of infliximab for those patients to receive infliximab.
  • Inability to comply with study procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00583232

Locations
United States, Indiana
Indiana University-Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University
GlaxoSmithKline
Crohn's and Colitis Foundation
Investigators
Principal Investigator: Steven J. Steiner, MD Indiana University
  More Information

No publications provided

Responsible Party: Steven Steiner, MD, Indiana University
ClinicalTrials.gov Identifier: NCT00583232     History of Changes
Other Study ID Numbers: 0506-19, IRB 0506-19
Study First Received: December 20, 2007
Last Updated: June 22, 2011
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Indiana University:
Pediatric
Crohn's disease
protein metabolism
energy metabolism

Additional relevant MeSH terms:
Crohn Disease
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on October 23, 2014